Ann: P2 trial shows significant improvements in Phelan-McDermid, page-124

only for another year? I've been here for 10 years and plan to be for another 20, God willing.

Wouldn't it be great if the market valued NEU as an independent company so highly that it would too expensive for Big Pharma to be interested in making a takeover bid. NEU could be in the top ASX50 along with CSL, our IP stays in the NZ/Aus region and leads to domestic manufacturing of our drugs, adding to high skilled, highly paid employment, and broadening the base of Australia's economy beyond the miners, banks and retailers. CSL is trading at a PE multiple of around 40, which has obviously made it too expensive for BP to take it over. That begs the question of where does the market expect CSL's growth of earnings to come from to justify such a high PE relative to the banks, retailers and miners. I reckon NEU has a much higher prospect of a massive lift in earnings over the next 10 years than CSL has, so once the market gains confidence in the sustainability and growth of our earnings from Daybue, and NNZ2591 progresses towards commercialisation, our PE ought be at least double CSL's.